Medical Coverage Policy | Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover

EFFECTIVE DATE: 07|01|2014
POLICY LAST REVIEWED: 03|20|2024

OVERVIEW

Bone turnover markers are biochemical markers of either bone formation or bone resorption. Commercially available tests are available to assess some of these markers in urine and/or serum by high-performance liquid chromatography or immunoassay. Assessment of bone turnover markers is proposed to supplement bone mineral density measurement in the diagnosis of osteoporosis and to aid in treatment decisions. Bone turnover markers could also potentially be used to evaluate treatment effectiveness before changes in bone mineral density can be observed.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

Medicare Advantage Plans and Commercial Products

Measurement of bone turnover markers using Collagen Crosslinks testing for the following indications may be considered medically necessary when filed with a covered diagnosis code. Refer to Coding section for details.

- Identify individuals with elevated bone resorption, who have osteoporosis in whom response to treatment is being monitored;
- Predict response (as assessed by bone mass measurements) to FDA approved antiresorptive therapy in postmenopausal women; and
- Assess response to treatment of patients with osteoporosis, Paget's disease of the bone, or risk for osteoporosis where treatment may include FDA approved antiresorptive agents, anti-estrogens or selective estrogen receptor moderators.

Measurement of all other bone turnover markers (i.e. Osteocalcin test) are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products the following indications:

- to determine fracture risk in individuals with osteoporosis or with age-related risk factors for osteoporosis
- to determine response to therapy in individuals who are being treated for osteoporosis
- in the management of individuals with conditions associated with high rates of bone turnover, including but not limited to Paget disease, primary hyperparathyroidism, and renal osteodystrophy.

Commercial Products

Some genetic testing services are not covered and a contract exclusion for any self-funded group that has excluded the expanded coverage of biomarker testing related to the state mandate, R.I.G.L**. §27-19-81** described in the Biomarker Testing Mandate policy. For these groups, a list of which genetic testing services are covered with prior authorization, are not medically necessary or are not covered because they are a contract exclusion can be found in the Coding section of the Genetic Testing Services or Proprietary Laboratory Analyses policies. Please refer to the appropriate Benefit Booklet to determine whether the member's plan has customized benefit coverage. Please refer to the list of Related Policies for more information.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for laboratory tests and applicable not covered/not medically necessary benefits/coverage.

BACKGROUND

Bone Turnover

After cessation of growth, bone is in a constant state of remodeling (or turnover), with initial absorption of bone by osteoclasts followed by deposition of new bone matrix by osteoblasts. This constant bone turnover is critical to the overall health of the bone, by repairing microfractures and remodeling the bony architecture in response to stress. Normally, the action of osteoclasts and osteoblasts is balanced, but bone loss occurs if the 2 processes become uncoupled. Bone turnover markers can be categorized as bone formation markers or bone resorption markers and can be identified in serum and/or urine. There is interest in the use of bone turnover markers to evaluate age-related osteoporosis, a condition characterized by slow, prolonged bone loss, resulting in an increased risk of fractures at the hip, spine, or wrist. Measurement of bone turnover markers may aid in the diagnosis (by determining fracture risk) and therapeutic monitoring (by determining response to treatment) of osteoporosis. Bone turnover markers may also be used for the management of other diseases associated with high bone turnover (eg, primary hyperparathyroidism, Paget disease, renal osteodystrophy).

Collagen Crosslinks

Generally speaking, collagen crosslink testing is useful mostly in "fast losers" of bone. The age when these bone markers can help direct therapy is often pre-Medicare. By the time a fast loser of bone reaches age 65, she will most likely have been stabilized by appropriate therapy or have lost so much bone mass that further testing is useless. Coverage for bone marker assays may be established, however, for younger Medicare beneficiaries and for those men and women who might become fast losers because of some other therapy such as glucocorticoids. Safeguards should be incorporated to prevent excessive use of tests in patients for whom they have no clinical relevance.

Collagen crosslinks testing is used to:

1. Identify individuals with elevated bone resorption, who have osteoporosis in whom response to treatment is being monitored;
2. Predict response (as assessed by bone mass measurements) to FDA approved antiresorptive therapy in postmenopausal women; and
3. Assess response to treatment of patients with osteoporosis, Paget's disease of the bone, or risk for osteoporosis where treatment may include FDA approved antiresorptive agents, anti-estrogens or selective estrogen receptor moderators.

Because of significant specimen to specimen collagen crosslink physiologic variability (15-20%), current recommendations for appropriate utilization include: one or two base-line assays from specified urine collections on separate days; followed by a repeat assay about three months after starting anti-resorptive therapy; followed by a repeat assay in 12 months after the three-month assay; and thereafter not more than annually, unless there is a change in therapy in which circumstance an additional test may be indicated three months after the initiation of new therapy. Some collagen crosslink assays may not be appropriate for use in some disorders, according to FDA labeling restrictions.

Measurement of All Other Bone Turnover Markers (i.e. Osteocalcin Test)

For individuals with osteoporosis or risk factors for age-related osteoporosis who receive a measurement of bone turnover markers to determine fracture risk, the evidence includes observational studies on the association between markers and osteoporosis and fracture risk, and systematic reviews of those studies. Relevant outcomes are test validity and morbid events. Few studies have directly addressed whether any bone turnover markers beyond bone mineral density (BMD) measurements are independent predictors of fracture risk. Some studies have suggested that bone turnover marker levels may be independently associated with osteoporosis and fracture risk in some groups, but there is insufficient evidence reporting on an association

with any specific marker. Questions remain whether bone turnover markers are sufficiently sensitive to determine reliably individual treatment responses. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are being treated for osteoporosis who receive a measurement of bone turnover markers to determine response to therapy, the evidence includes an observational study, randomized controlled trials (RCTs), and a systematic review these RCTs. Relevant outcomes are test validity and morbid events. There is limited evidence on the impact of bone turnover markers on the management of osteoporosis. Individual RCTs and a systematic review of these RCTs have not found that feedback on bone turnover marker improves treatment adherence rates. No studies were identified that evaluated whether the use of bone turnover markers leads to management changes that are expected to improve outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with conditions associated with high rates of bone turnover other than age-related osteoporosis (eg, primary hyperparathyroidism, Paget disease, renal osteodystrophy) who receive a measurement of bone turnover markers, the evidence includes observational studies on the association between markers and disease activity and a systematic review of those studies. Relevant outcomes are test validity and morbid events. The largest amount of evidence has been published on Paget disease; a systematic review found correlations between several bone turnover markers and disease activity prior to and/or after bisphosphonate treatment. There is a lack of evidence on how the measurement of bone turnover markers can change patient management or improve health outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

CODING

Medicare Advantage Plans and Commercial Products

The following CPT code(s) are covered when filed with one of the diagnosis codes in the attachments below:

82523 Collagen cross links, any method

Covered ICD-10 Codes for CPT Code 82523

The following CPT code(s) are not covered for Medicare Advantage Plans and not medically necessary for Commercial Products when filed with an ICD-10 Diagnosis Code* listed below;

83937 Osteocalcin (bone g1a protein)

***Not medically necessary ICD-10 Diagnosis Codes**:

M81.0-M81.8
Z13.820
Z82.62

RELATED POLICIES

Biomarker Testing Mandate
Genetic Testing Services

PUBLISHED

Provider Update, May 2024
Provider Update, April 2023
Provider Update, April 2022
Provider Update, March 2021
Provider Update, April 2020

REFERENCES

1. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Collagen Crosslinks, any Method (190.19).
2. Rules and Regulations: Medicare National Coverage Decision for Collagen Crosslinks, Any Method Other Names/Abbreviations. Federal Register. 2001;66(226):58843-58844.

3. Kim JM, Lin C, Stavre Z, et al. Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells. Sep 10 2020; 9(9). PMID32927921
4. Greenblatt MB, Tsai JN, Wein MN. Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. ClinChem. Feb 2017; 63(2): 464-474. PMID 27940448
5. Shetty S, Kapoor N, Bondu JD, et al. Bone turnover markers: Emerging tool in the management of osteoporosis. Indian JEndocrinol Metab. 2016; 20(6): 846-852. PMID 27867890
6. Szulc P, Naylor K, Hoyle NR, et al. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliancerecommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int.Sep 2017; 28(9): 2541-2556. PMID 28631236
7. Tian A, Ma J, Feng K, et al. Reference markers of bone turnover for prediction of fracture: a meta-analysis. J Orthop Surg Res.Feb 28 2019; 14(1): 68. PMID 30819222
8. Johansson H, Odén A, Kanis JA, et al. A meta-analysis of reference markers of bone turnover for prediction of fracture. CalcifTissue Int. May 2014; 94(5): 560-7. PMID 24590144
9. Biver E, Chopin F, Coiffier G, et al. Bone turnover markers for osteoporotic status assessment? A systematic review of theirdiagnosis value at baseline in osteoporosis. Joint Bone Spine. Jan 2012; 79(1): 20-5. PMID 21724445
10. Tamaki J, Iki M, Kadowaki E, et al. Biochemical markers for bone turnover predict risk of vertebral fractures in postmenopausalwomen over 10 years: the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int. Mar 2013; 24(3):887-97. PMID 22885773
11. Bauer DC, Garnero P, Harrison SL, et al. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: theMrOS study. J Bone Miner Res. Dec 2009; 24(12): 2032-8. PMID 19453262
12. Zhang T, Liu P, Zhang Y, et al. Combining information from multiple bone turnover markers as diagnostic indices forosteoporosis using support vector machines. Biomarkers. Mar 2019; 24(2): 120-126. PMID 30442069
13. Gutierrez-Buey G, Restituto P, Botella S, et al. Trabecular bone score and bone remodelling markers identify perimenopausalwomen at high risk of bone loss. Clin Endocrinol (Oxf). Sep 2019; 91(3): 391-399. PMID 31141196
14. Shieh A, Greendale GA, Cauley JA, et al. Urinary N-Telopeptide as Predictor of Onset of Menopause-Related Bone Loss inPre- and Perimenopausal Women. JBMR Plus. Apr 2019; 3(4): e10116. PMID 31044185
15. Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate:the fracture intervention trial. J Bone Miner Res. Feb 2006; 21(2): 292-9. PMID 16418785
16. Kashii M, Kamatani T, Nagayama Y, et al. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int. Mar 2023; 34(3): 563-572. PMID 36585509
17. Baxter I, Rogers A, Eastell R, et al. Evaluation of urinary N-telopeptide of type I collagen measurements in the management ofosteoporosis in clinical practice. Osteoporos Int. Mar 2013; 24(3): 941-7. PMID 22872068
18. Burch J, Rice S, Yang H, et al. Systematic review of the use of bone turnover markers for monitoring the response toosteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. HealthTechnol Assess. Feb 2014; 18(11): 1-180. PMID 24534414
19. Roux C, Giraudeau B, Rouanet S, et al. Monitoring of bone turnover markers does not improve persistence with ibandronatetreatment. Joint Bone Spine. Jul 2012; 79(4): 389-92. PMID 21703900
20. Al Nofal AA, Altayar O, BenKhadra K, et al. Bone turnover markers in Paget's disease of the bone: A Systematic review andmeta-analysis. Osteoporos Int. Jul 2015; 26(7): 1875-91. PMID 26037791
21. Martlı HF, Saylam B, Er S, et al. Evaluation of preoperative procollagen type 1 N-terminal peptide and collagen type 1 C-telopeptide levels in the prediction of postoperative hypocalcemia in patients undergoing parathyroidectomy due to primary hyperparathyroidism. Langenbecks Arch Surg. Jan 31 2023; 408(1): 71. PMID 36720758
22. Rianon N, Alex G, Callender G, et al. Preoperative serum osteocalcin may predict postoperative elevated parathyroid hormonein patients with primary hyperparathyroidism. World J Surg. Jun 2012; 36(6): 1320-6. PMID 22278606

23. Camacho PM, Petak SM, Binkley N, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocr Pract. May 2020; 26(Suppl 1): 1-46. PMID 32427503
24. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. Oct 2022; 33(10): 2049-2102. PMID 35478046
25. Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: AnEndocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. May 01 2019; 104(5): 1595-1622. PMID 30907953
26. Shoback D, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: AnEndocrine Society Guideline Update. J Clin Endocrinol Metab. Mar 01 2020; 105(3). PMID 32068863
27. Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an endocrine society clinical practice guideline. J ClinEndocrinol Metab. Dec 2014; 99(12): 4408-22. PMID 25406796
28. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. Sep 01 2021; 28(9): 973-997. PMID 34448749
29. McCloskey EV, Vasikaran S, Cooper C, et al. Official Positions for FRAX® clinical regarding biochemical markers from JointOfficial Positions Development Conference of the International Society for Clinical Densitometry and International OsteoporosisFoundation on FRAX®. J Clin Densitom. 2011; 14(3): 220-2. PMID 21810528
30. Kendler DL, Compston J, Carey JJ, et al. Repeating Measurement of Bone Mineral Density when Monitoring with Dual-energy X-ray Absorptiometry: 2019 ISCD Official Position. J Clin Densitom. 2019; 22(4): 489-500. PMID 31378452
31. U.S. Preventive Services Task Force (USPSTF). Osteoporosis to Prevent Fractures: Screening. June 2018. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosisscreening#Full recommendation start. Accessed November 10, 2023.

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.